|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
From the Department of HIV Medicine and Department of
Oncology, Chelsea and Westminster Hospital, London, United Kingdom.
Clinical data on 7840 HIV-positive patients, representing 43 745
patient-years of follow-up, has been collected. All patients with ARL
since 1986 (n = 150) were assessed at presentation for prognostic
factors and outcomes recorded. Comparisons are made between cases in
the pre-HAART era (1988-1995), and the HAART era (1996-1999).
Statistical models are used to calculate the incidence of ARL and
factors predicting its development. The incidence of ARL has not
changed over time (3 to 7 of 1000 patients per year,
P = .933), but contributes to a greater percentage of
first AIDS-defining illnesses (ADI) in the HAART era
(P High-grade B-cell non-Hodgkin lymphoma (NHL) has
been classified as an AIDS-defining illness (ADI) since 1985, following
the description of NHL in a group of 90 HIV-1 seropositive
men.1 It has since been recognized to occur in AIDS
patients at a frequency more than 100 times that of the general
population.2 AIDS-related lymphoma (ARL) appears to be
slightly more common in hemophiliacs and less common in intravenous
drug users compared with other HIV transmission groups.3
In the era before highly active antiretroviral therapy (pre-HAART)
(before 1996), the incidence of AIDS-related lymphoma remained fairly
constant at around 6 to 7 cases per 1000 person-years.4
The annual occurrence of NHL as a percentage of all ADIs in 1994 was
estimated at 3.0% in the United States2 and 3.6% in
Europe.5 As a first ADI, NHL occurred in only 1.5% of
cases. Because the development of ARL is associated with a relative
risk of death of 20.56,6 HIV-associated NHL consequently accounted for up to 16% of all deaths attributable to AIDS.
The widespread introduction of HAART since 1996 has led to dramatic
reductions in AIDS-related morbidity and mortality throughout the
developed world.7,8 This is largely due to a marked fall in the incidence of the major opportunistic infections such as Pneumocystis carinii pneumonia (PCP), cytomegalovirus (CMV),
and Mycobacterium avium complex (MAC). Although this trend
has also been observed for Kaposi sarcoma, the effect on NHL has not
been so clear. Ledergerber et al9 have recently reported
from the Swiss HIV Cohort Study. A substantial relative risk reduction from 1992-1994 to 1997-1998 was seen for the development of Kaposi sarcoma as well as for other AIDS-defining conditions. No significant trend was seen for NHL, implying an ongoing risk for patients, despite
the use of potent antiretroviral therapies. Other groups from the
United States confirm this finding. The US AIDS Clinical Trial Group
(ACTG) found the incidence rates for both Kaposi sarcoma and NHL to be
decreasing, but the former far more profoundly and consistently.10 In contrast, a group from the San
Francisco City Clinic found the incidence of lymphoma between 1993 and
1996 to be unchanged at 1.4 to 1.8 per 100 person-years,11
whereas the Multicenter AIDS Cohort Study (MACS) actually found an
increase in the incidence of NHL at a rate of 21% per
year.12 During the same period, the incidence of Kaposi
sarcoma fell by 66%.
As a percentage of first ADIs, NHL has increased. In western Europe, it
rose from 3.6% in 1994 to 4.9% in 1997.5 This is likely
to reflect the reduction in other causes of AIDS rather than a true
rise in NHL incidence. It may be that with increasing use and duration
of HAART, both the incidence and characteristics of AIDS-related
lymphoma will change. Most published studies have only reported
follow-up to 1997. We reviewed the incidence, presentation, and
survival of all patients with lymphoma treated in our clinic from 1986 to October 1999.
Clinical data on all individual HIV-1 seropositive patients
attending the Chelsea and Westminster Hospital (CWH) have been prospectively collected since 1981, and these patients comprise the
total population at risk of developing lymphoma in our study. This
database contains information on 7840 patients and represents 43 745
patient-years of follow-up. The incidence of NHL has been calculated
using the total numbers of HIV- seropositive patients attending the CWH
each year as the denominator. Information on patient demographics
including age, sex, ethnicity, and mode of HIV transmission are
recorded. Other information extracted from the database includes AIDS
diagnoses, CD4 cell counts, and history of antiretroviral therapy. As
HIV viral load data have been available only since 1996, we did not
include this in the analysis presented.
For the purposes of this study, only patients with systemic NHL were
included as cases (excluding cases of Hodgkin disease and primary
central nervous system lymphoma). All cases were confirmed by
diagnostic histology. The characteristics of the patients with systemic
NHL were compared with those of the general HIV clinic population to
identify significant predictors of lymphoma development. Lymphoma cases
were also divided on the basis of their date of NHL diagnosis into the
pre-HAART era (defined as before 1996) and the HAART era (defined as
1996-1999), and more specifically, into patients who had treatment with
HAART before NHL diagnosis and those who had not. Comparisons of the
incidence, clinical details, and survival of patients who developed NHL
during the 2 periods are described.
Statistical methods
A log-linear regression analysis was used to determine the incidence of
NHL. A log transformed person time at risk was used as a rate
multiplier in the log-linear model. A person time at risk was defined
as entry into the study as an HIV positive case until either
development of NHL, or if not an NHL case, then either the date of
death or the most recent follow-up. Therefore, a person who has NHL
would no longer contribute to patient time of follow-up since having
NHL and any further clinical observation on that patient would be
excluded from the analysis.
All P values are 2-sided. Log-linear regression models
were used to derive incidence rates per patient year and the
corresponding rate ratios. These were derived using the GENMOD
procedure in SAS (Cary, NC) with the assumption that NHL events
occurred randomly and followed a Poisson distribution.
Incidence of non-Hodgkin lymphoma
Factors involved in the development of non-Hodgkin lymphoma The univariate log-linear model showed a significant association between age at entry to the study and incidence of NHL, whether age was assessed as a continuous variable or grouped by quartiles (Table 3). The incidence of lymphoma in a patient presenting over the age of 37 years was shown to be over 3 times that of patients who were under 26 years old (P .001). There were no significant differences in the
incidence of NHL by gender (P = .14), ethnicity
(P = .37), intravenous drug use (P = .27), or year of entry to the study (P = .88).
First recorded and nadir CD4 cell count are presented in the univariate model. Five NHL patients had neither count available; these patients had been found to be HIV positive at the time of NHL diagnosis and died very shortly afterward. The CD4 count nadir, and first recorded CD4 count, were both strongly associated with the development of lymphoma. As the CD4 count fell, the development of lymphoma became more likely. Of note, in this analysis, CD4 counts are analyzed and presented in statistical quartiles. The incidence of NHL was twice that in patients whose first-ever CD4 count was below 305 cells/µL compared with those whose first-ever CD4 was above 305 cells/µL. A similar trend was seen in patients whose nadir CD4 count fell below 114 cells/µL, compared with those whose nadir CD4 remained above 114 cells/µL. If a specific nadir CD4 count of 350 cells/µL is taken (the level at which initiation of treatment is advocated in the UK), a steep rise in incidence below this level is seen. Above 350 cells/µL, the incidence of NHL is 0.7 cases per 10 000 patient-years, whereas below this level, it rises to 10 cases per 10 000 patient-years (P < .001). Indeed, only 2 of the 150 patients had a nadir CD4 count of more than 350 cells/µL. The only other variable shown to be protective against the development of NHL was the use of HAART (defined as an antiretroviral regimen containing at least one protease inhibitor or non-nucleoside reverse transcriptase inhibitor). Seventeen NHL patients had experienced a HAART-containing regime before the diagnosis of NHL, as opposed to 133 either naïve to therapy or treated with nucleosides alone. The incidence of NHL was significantly lower in patients who had been treated with HAART (P < .001) A multivariate log-linear model was used to determine independent
predictors of NHL. Those variables found to be significant in the
univariate log-linear model were entered into the multivariate model. A
conservative P value selection criteria
(P < .1) was used to enter variables into the
multivariate model. As nadir CD4 counts and first recorded CD4 counts
are correlated with each other, only nadir CD4 count was selected for
entry. Older age at entry and nadir CD4 count were found to be
independent significant predictors of NHL incidence, as was the use of
HAART (P < .001) (Table
4). The incidence estimates presented in
Table 4 are adjusted for gender, ethnicity, intravenous drug use,
and year of entry to the study.
Clinical features of systemic non-Hodgkin lymphoma The patients with systemic NHL have been divided into 2 cohorts that correspond to the introduction of HAART (Table 5). The cohorts were analyzed for established prognostic factors at NHL presentation. There has been no significant change in the stage of NHL at presentation, presence of B symptoms, ECOG (Eastern Cooperative Oncology Group) performance status, or bone marrow involvement between the 2 cohorts. However, in the recent cohort, fewer patients had a prior AIDS-defining illness, CD4 cell counts were higher, and patients were older. Those patients diagnosed with NHL within the HAART era were then further subdivided into 2 groups on the basis of whether they had actually received HAART before NHL diagnosis (Table 6). Those patients who had received prior HAART (n = 17) had higher CD4 counts but otherwise presented with similar clinical features to the group with no prior HAART exposure (n = 34).
Survival of systemic non-Hodgkin lymphoma The overall survival of the pre- and post-HAART era cohorts are not significantly different (Mantel Cox log rank P = .15) with 2-year overall survivals of 29.0% (95% CI: 19.6%-38.4%) for the pre-HAART cohort, and 41.2% (95%CI: 26.2%-56.2%) for the more recent cohort (Figure 2). There is also no survival difference seen between those patients in the 1996-1999 era with HAART exposure before NHL diagnosis and those with no prior HAART exposure (log-rank P = .12, data not shown). This lack of significant improvement in overall survival may simply reflect insufficient sample size and follow-up, but is of concern, given that some prognostic factors such as prior AIDS diagnosis and median CD4 count are more favorable in the recent cohort.
The development of non-Hodgkin lymphoma in association with HIV-1
infection is not only more common than in the general population, but
is also associated with a less favorable outcome. This study describes
our experience with lymphoma in this setting over the past 11 years.
During this time, potent therapies for the treatment of HIV infection
have become available, and morbidity and mortality have plummeted.
Despite this, the incidence of NHL remains largely unchanged We have shown that older age, nadir CD4 count, and nonuse of HAART are all independently associated with the development of NHL. Increasing age is well recognized as a risk factor for the development of lymphoma in all patient groups, and the extended life span of HIV patients after the introduction of HAART may ultimately contribute to a larger "at-risk" population. Unlike opportunistic infections, the development of NHL is unlikely to be the result of exposure to one single pathogen, but rather a consequence of several different events. It is, nevertheless, clearly linked to all forms of cellular immunosuppression, and both the absolute nadir CD4 count and the duration of nadir are likely to be important. The relationship to CD4 count is confirmed in our model showing that both first recorded and nadir CD4 counts are important predictors of NHL development. Because, in our study, the use of HAART has a significant protective effect on the development of NHL, it is hoped that the widespread use of these therapies, started before the nadir CD4 count drops below a critical level, may eventually help reduce the number of new cases of NHL. Recent data from the EuroSIDA study confirm that the nadir CD4 count has an important effect on HIV-1 disease progression, even if HAART is later able to induce a subsequent good CD4 rise.14 What constitutes a "safe" nadir CD4 count is more difficult to predict, although our study shows the incidence of NHL above a nadir CD4 of 350 cells/µL to be low (0.7 cases per 10 000 patient-years). Early series reported the most influential prognostic variables for survival to be related to the severity of immunosuppression rather than lymphoma-related factors. Multivariate analysis of 2 series revealed that the CD4 count at diagnosis, a history of a prior AIDS-defining diagnosis, a poor performance status, and bone marrow involvement, were independent adverse prognostic factors.15,16 An International Prognostic Index for lymphoma has since been introduced for aggressive lymphomas in the non-HIV-infected population.17 Recent prospective data from an AIDS Clinical Trials Group (ACTG) study have suggested that the prognostic variables in ARL closely resemble those in the International Prognostic Index for non-HIV-associated NHL.18 In our cohort, those patients with NHL presenting since 1996 show no significant change in prognostic factors relating to the tumor itself (B symptoms, stage of disease, ECOG performance status) whether treated with HAART before their lymphoma diagnosis or not. Those patients on HAART had significantly higher CD4 counts at NHL diagnosis but there are no differences in other prognostic variables or overall survival. This study suggests that HAART may reduce the likelihood of developing systemic lymphoma but does not alter the natural history of NHL in people with HIV-1 infection. In conclusion, it remains to be seen whether the incidence of NHL will eventually fall, similar to that of other opportunistic infections and Kaposi sarcoma. A significant number of patients (19% in our study) may always present with NHL unaware of their HIV diagnosis. For known HIV-positive patients however, our data suggest that better preservation of long-term immunologic function with HAART may translate into a future fall in the number of new cases of NHL.
Submitted July 7, 1999; accepted June 15, 2000.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Mark Bower, Department of Oncology, Chelsea and Westminster Hospital, 369 Fulham Rd, London SW10 9NH, UK.
1. Ziegler JL, Beckstead JA, Volberding PA, et al. Non-Hodgkin's lymphoma in 90 homosexual men: relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome. N Engl J Med. 1984;311:565-570[Abstract]. 2. Goedert JJ, Tote TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet. 1998;351:1833-1839[Medline] [Order article via Infotrieve]. 3. Beral V, Peterman T, Berkelman R, et al. AIDS-associated non-Hodgkin's lymphoma. Lancet. 1991;337:805-809[Medline] [Order article via Infotrieve]. 4. Surveillance for AIDS-defining opportunistic illnesses 1992-7. CDC Surveillance Summaries. MMWR Morb Mortal Wkly Rep. 1999;48:SS-2. 5. Franchesi S, Dal Maso L, La Vecchia C. Advances in the epidemiology of HIV-associated non-Hodgkin's lymphoma and other lymphoid neoplasms. Int J Cancer 1999;83:481-485[Medline] [Order article via Infotrieve]. 6. Petruckevitch A, Del Amo J, Phillips AN, et al. Disease progression and survival following specific AIDS-defining conditions; a retrospective cohort study of 2048 HIV-infected persons in London. AIDS. 1998;12:1007-1013[Medline] [Order article via Infotrieve].
7.
Palella FJ, Delaney KM, Moorman AC, et al.
and the HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced immunodeficiency virus Infection.
N Engl J Med.
1998;338:853-860 8. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1: EuroSIDA Study Group. Lancet. 1998;352:1725-1730[Medline] [Order article via Infotrieve].
9.
Ledergerber B, Telenti A, Egger M, et al.
Risk of HIV-related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study.
BMJ.
1999;319:23-24 10. Rabkin CS, Testa M, Von Roenn JH. Kaposi's sarcoma and non-Hodgkin's lymphoma incidence trends in AIDS Clinical Trial Group study participants. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;21(suppl 1):S31-33. 11. Buchbinder SP, Holmberg S, Scheer S, et al. Combination antiretroviral therapy and incidence of AIDS-related malignancies. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;21(suppl 1):S23-26. 12. Jacobsen LP, Yamashita TE, Margolick JB, et al. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma among HIV-1 infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;21(suppl 1):S34-41. 13. Bower M, Fife K, Sullivan A, et al. Treatment outcome in presumed and confirmed AIDS-related primary cerebral lymphoma. Eur J Cancer. 1999;35:601-604.
14.
Miller V, Mocroft A, Reiss P, et al.
Relations among CD4 lymphocyte count nadir, antiretroviral therapy and HIV-1 disease progression: results from the EuroSIDA study.
Ann Intern Med.
1999;130:570-577
15.
Kaplan LD, Abrams DI, Feigal E, et al.
AIDS-associated non-Hodgkin's lymphoma in San Francisco.
JAMA.
1989;261:719-724 16. Levine AM, Sullivan Halley J, Pike MC, et al. Human immunodeficiency virus-related lymphoma: prognostic factors predictive of survival. Cancer 1991;68:2466-2472[Medline] [Order article via Infotrieve].
17.
The International Non-Hodgkin's Lymphoma Prognostic Factors Project: a predictive model for aggressive non-Hodgkin's lymphoma.
N Engl J Med.
1993;329:987-994 18. Straus DJ, Huang J, Testa MA, Levine AM, Kaplan LD. Prognostic factors in the treatment of human immunodeficiency virus-associated lymphoma; analysis of AIDS Clinical Trials Group protocol 142-low-dose versus standard dose m-BACOD plus granulocyte-macrophage colony-stimulating factor: National Institute of Allergy and Infectious Diseases. J Clin Oncol. 1998;16:3601-3606[Abstract].
© 2000 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  M. Bower, M. Fisher, T. Hill, I. Reeves, J. Walsh, C. Orkin, A. N. Phillips, L. Bansi, R. Gilson, P. Easterbrook, et al. CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK Haematologica, June 1, 2009; 94(6): 875 - 880. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Balsalobre, J. L. Diez-Martin, A. Re, M. Michieli, J. M. Ribera, C. Canals, A. Rosselet, E. Conde, R. Varela, K. Cwynarski, et al. Autologous Stem-Cell Transplantation in Patients With HIV-Related Lymphoma J. Clin. Oncol., May 1, 2009; 27(13): 2192 - 2198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Galicier, C. Fieschi, R. Borie, V. Meignin, M.-T. Daniel, L. Gerard, and E. Oksenhendler Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study Blood, October 15, 2007; 110(8): 2846 - 2854. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Palmieri, T. Treibel, O. Large, and M. Bower AIDS-related non-Hodgkin's lymphoma in the first decade of highly active antiretroviral therapy QJM, December 1, 2006; 99(12): 811 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Mounier, M. Spina, J. Gabarre, M. Raphael, G. Rizzardini, J.-B. Golfier, E. Vaccher, A. Carbone, B. Coiffier, G. Chichino, et al. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy Blood, May 15, 2006; 107(10): 3832 - 3840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bower, B. Gazzard, S. Mandalia, T. Newsom-Davis, C. Thirlwell, T. Dhillon, A. M. Young, T. Powles, A. Gaya, M. Nelson, et al. A Prognostic Index for Systemic AIDS-Related Non-Hodgkin Lymphoma Treated in the Era of Highly Active Antiretroviral Therapy Ann Intern Med, August 16, 2005; 143(4): 265 - 273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. T. Lim and A. M. Levine Recent Advances in Acquired Immunodeficiency Syndrome (AIDS)-related Lymphoma CA Cancer J Clin, July 1, 2005; 55(4): 229 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Cheung, L. Pantanowitz, and B. J. Dezube AIDS-Related Malignancies: Emerging Challenges in the Era of Highly Active Antiretroviral Therapy Oncologist, June 1, 2005; 10(6): 412 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bower, N. McCall-Peat, N. Ryan, L. Davies, A. M. Young, S. Gupta, M. Nelson, B. Gazzard, and J. Stebbing Protease inhibitors potentiate chemotherapy-induced neutropenia Blood, November 1, 2004; 104(9): 2943 - 2946. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Levine, A. Tulpule, B. Espina, A. Sherrod, W. D. Boswell, R. D. Lieberman, B. N. Nathwani, and L. Welles Liposome-Encapsulated Doxorubicin in Combination With Standard Agents (cyclophosphamide, vincristine, prednisone) in Patients With Newly Diagnosed AIDS-Related Non-Hodgkin's Lymphoma: Results of Therapy and Correlates of Response J. Clin. Oncol., July 1, 2004; 22(13): 2662 - 2670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Stebbing, B. Gazzard, S. Mandalia, A. Teague, A. Waterston, V. Marvin, M. Nelson, and M. Bower Antiretroviral Treatment Regimens and Immune Parameters in the Prevention of Systemic AIDS-Related Non-Hodgkin's Lymphoma J. Clin. Oncol., June 1, 2004; 22(11): 2177 - 2183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Hartmann, U. Rehwald, B. Salzberger, C. Franzen, M. Sieber, A. Wohrmann, and V. Diehl BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection Ann. Onc., October 1, 2003; 14(10): 1562 - 1569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Kolber and M. O. Saenz Antigen-Presenting Cell Modulation Induces a Memory Response to p24 in Peripheral Blood Leukocytes from Human Immunodeficiency Virus-Infected Individuals Clin. Vaccine Immunol., September 1, 2003; 10(5): 757 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Roychowdhury, R. Peng, R. A. Baiocchi, D. Bhatt, S. Vourganti, J. Grecula, N. Gupta, C. F. Eisenbeis, G. J. Nuovo, W. Yang, et al. Experimental Treatment of Epstein-Barr Virus-associated Primary Central Nervous System Lymphoma Cancer Res., March 1, 2003; 63(5): 965 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Oksenhendler, E. Boulanger, L. Galicier, M.-Q. Du, N. Dupin, T. C. Diss, R. Hamoudi, M.-T. Daniel, F. Agbalika, C. Boshoff, et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease Blood, April 1, 2002; 99(7): 2331 - 2336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Krishnan, A. Molina, J. Zaia, A. Nademanee, N. Kogut, J. Rosenthal, D. Woo, and S. J. Forman Autologous stem cell transplantation for HIV-associated lymphoma Blood, December 15, 2001; 98(13): 3857 - 3859. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Kirk, C. Pedersen, A. Cozzi-Lepri, F. Antunes, V. Miller, J. M. Gatell, C. Katlama, A. Lazzarin, P. Skinhoj, and S. E. Barton Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy Blood, December 1, 2001; 98(12): 3406 - 3412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Besson, A. Goubar, J. Gabarre, W. Rozenbaum, G. Pialoux, F.-P. Chatelet, C. Katlama, F. Charlotte, B. Dupont, N. Brousse, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy Blood, October 15, 2001; 98(8): 2339 - 2344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Levine, D. T. Scadden, J. A. Zaia, and A. Krishnan Hematologic Aspects of HIV/AIDS Hematology, January 1, 2001; 2001(1): 463 - 478. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2000 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
a finding
confirmed by other studies.